Eliaschewitz, Freddy G.
Canani, Luis Henrique
Funding for this research was provided by:
novo nordisk farmacĂȘutica do brasil ltda
Article History
Received: 18 June 2021
Accepted: 23 August 2021
First Online: 15 September 2021
Declarations
:
: Not applicable.
: If the manuscript is accepted, I agree to its publication in Diabetology and Metabolic Syndrome.
: FGE: Advisory board for AstraZeneca, Novonordisk, Sanofi. Lectures: Bayer, Lilly, AstraZeneca, Novo Nordisk, Sanofi, Abbott, Merck, Novartis. LHC: Speaker for Novo Nordisk. Researcher in the PIONEER Program.